| Cas No.: | 155206-00-1 |
| 名称: | (Z)-7-((1R,2R,3S,5S)-3,5-dihydroxy-2-((E)-3-hydroxy-5-phenylpent-1-enyl)cyclopentyl)-N-ethylhept-5-enamide |
| 别名: | Lumigan |
| SMILES: | C(NCC)(=O)CCC/C=C\C[C@@H]1[C@H](O)C[C@@H](O)[C@H]1/C=C/C(O)CCC1=CC=CC=C1 |
| 分子式: | C25H37NO4 |
| 分子量: | 415.57 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | Bimatoprost is converted by an amidase enzymatic activity in bovine and human cornea models to yield the corresponding free acid, 17-phenyl trinor PGF2α, a potent PGF2αR agonist. In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity. For the detailed information of Bimatoprost, the solubility of Bimatoprost in water, the solubility of Bimatoprost in DMSO, the solubility of Bimatoprost in PBS buffer, the animal experiment（test） (test) of Bimatoprost, the cell expriment (test) of Bimatoprost, the in vivo, in vitro and clinical trial test of Bimatoprost, the EC50, IC50,and Affinity of Bimatoprost,, please contact DC Chemicals. |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
